MGB 453Alternative Names: MGB453
Latest Information Update: 30 Oct 2015
At a glance
- Originator Novartis
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action CD223 antigen inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Cancer
Most Recent Events
- 21 Oct 2015 Preclinical trials in Cancer in USA (IV) prior to October 2015